No red flags in insider behavior, sales are small and offset by grants and exercises. Monitor next earnings report for fundamentals; this activity does not suggest material non-public information.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $63.33entry
- T+1 · 9mo ago −0.81%α +0.51% · $62.82
- T+5 · 8mo ago +0.05%α +2.29% · $63.36
- T+20 · 8mo ago +7.01%α +10.80% · $67.77
- T+60 · 6mo ago +16.53%α +5.23% · $73.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PTC Therapeutics CEO Matthew Klein sold $170,600 of stock in an open-market transaction, while Director Stephanie Okey exercised options and sold 1,167 shares for $81,700. The CEO also received a non-cash award of 12,500 shares. Total open-market sales in the cluster amount to $252,300, representing a minor 0.005% of the company's $5.2B market cap.
Key Financial Metrics
Key Facts
- CEO Matthew Klein sold 2,662 shares for $170,581 in an open-market transaction.
- CEO also received a non-cash grant of 12,500 shares (no economic cost).
- Director Stephanie Okey exercised options and sold 1,167 shares for $81,690.
- All transactions are within normal insider activity patterns; no large-scale selling or coordinated exits.
- Total open-market sales: $252,271 (0.005% of $5.2B market cap).
Financial Impact
$252,271 in total open-market sales; non-cash transactions account for $0 in economic outflow.
Risk Factors
- Perception risk if media highlights CEO sale without context of concurrent share award.
- Option exercises followed by sales may signal profit-taking, but not unusual for directors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-PTCT-1773436832176 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers